See why thousands choose our centers as their preferred destination for ongoing care, including Stelara SQ treatments.
On September 9, IVX Health was notified by the pharmaceutical manufacturer Janssen that three Medicare Administrative Contractors (MACs) – Palmetto, Noridian, and NGS - are adding the subcutaneous (injectable) formulation of its biologic therapy STELARA to their Self-Administered Drug (SAD) Exclusion List, effective October 15, 2021. Medicare will no longer cover STELARA SQ injections under the medical benefit (Part B) and instead will cover STELARA SQ under the prescription benefit (Part D). This change limits the ability of providers, including IVX, to administer STELARA for Medicare patients and generally requires patients remaining on STELARA SQ to self-administer the injection at home.
Due to this classification change, IVX Health is no longer accepting new STELARA SQ patients with Medicare across all markets. (IVX Health will continue to accept STELARA IV patients with Medicare.) In addition, this change affects care for existing IVX patients with Medicare in the following states:
- Railroad Medicare patients in all states
This change has immediate ramifications to patient care at IVX Health. IVX Health is proactively notifying referring providers about the classification change and the appropriate next steps for their patients. If you are an existing STELARA SQ patient at IVX Health and live in one of the aforementioned states, please contact your local IVX Health center immediately to discuss next steps.
Stelara SQ is an infusion therapy that is indicated to treat:
- moderately to severely active Crohn’s disease (CD) where treatment with immunomodulators, corticosteroids, or one or more TNF blockers failed
- active psoriatic arthritis
- moderate to severe plaque psoriasis with a candidacy for phototherapy or systemic therapy
Stelara SQ targets proteins, IL-12 and IL-23, which are thought to be associated with plaque psoriasis, gastrointestinal, joint and skin inflammation. For Crohn’s patients, Stelara is administered via a single infusion, typically at least one hour, and followed by an injection once every eight weeks until patients have received six total injections. For patients with psoriatic arthritis or plaque psoriasis, Stelara is administered subcutaneously at week one and week 4, followed by doses received every 12 weeks.
Patients chose IVX Health to receive their ongoing Stelara SQ treatments because:
- ALL private suites
- Comfortable recliners, with chairs for guests
- Evening & weekend appointments
- Friendly clinical staff deliver personal service
- Big screen TVs, high-speed WiFi, free snacks